A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)

• Register: ClinicalTrials.gov
• Last refreshed on: 22 February 2021
• Main ID: NCT02292537
• Date of registration: 12/11/2014
• Prospective Registration: Yes
• Primary sponsor: Biogen
• Public title: A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA) CHERISH
• Scientific title: A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Later-onset Spinal Muscular Atrophy
• Date of first enrolment: November 24, 2014
• Target sample size: 126
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT02292537
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
• Phase: Phase 3

Countries of recruitment

Canada, France, Germany, Hong Kong, Italy, Japan, Korea, Republic of, Spain, Sweden, United Kingdom, United States

Contacts

• Name: Medical Director
• Affiliation: Biogen

Key inclusion & exclusion criteria

Key Inclusion Criteria:

- Parent or guardian has signed informed consent and, if indicated per participant's age
and institutional guidelines, participant has signed informed assent

- Be medically diagnosed with Spinal Muscular Atrophy (SMA)

- Have onset of clinical signs and symptoms consistent with SMA at greater than 6 months
of age

- Be able to sit independently, but has never had the ability to walk independently

- Have Motor Function Score (Hammersmith Functional Motor Scale - Expanded) greater than
or equal to 10 and less than or equal to 54 at Screening

- Be able to complete all study procedures, measurements and visits and parent or
guardian and subject has adequately supportive psychosocial circumstances, in the
opinion of the Investigator

- Have an estimated life expectancy of greater than 2 years from Screening, in the
opinion of the Investigator

- Meet age-appropriate institutional criteria for use of anesthesia and sedation, if use
is planned for study procedures

- For subjects who have reached reproductive maturity, satisfy study contraceptive
requirements

Key Exclusion Criteria:

- Respiratory insufficiency, defined by the medical necessity for invasive or
non-invasive ventilation for greater than 6 hours during a 24 hour period, at
Screening

- Medical necessity for a gastric feeding tube, where the majority of feeds are given by
this route, as assessed by the Site Investigator

- Severe contractures or severe scoliosis evident on X-ray examination at Screening

- Hospitalization for surgery (i.e., scoliosis surgery, other surgery), pulmonary event,
or nutritional support within 2 months of Screening or planned during the duration of
the study

- Presence of an untreated or inadequately treated active infection requiring systemic
antiviral or antimicrobial therapy at any time during the screening period

- History of brain or spinal cord disease, including tumors, or abnormalities by
magnetic resonance imaging (MRI) or computed tomography (CT) that would interfere with
the LP procedures or cerebrospinal fluid (CSF) circulation

- Presence of an implanted shunt for the drainage of CSF or an implanted central nervous
system (CNS) catheter

- History of bacterial meningitis

- Dosing with IONIS-SMN Rx in any previous clinical study

- Prior injury (e.g., upper or lower limb fracture) or surgical procedure which impacts
the subject's ability to perform any of the outcome measure testing required in the
protocol and from which the subject has not fully recovered or achieved a stable
baseline

- Clinically significant abnormalities in hematology or clinical chemistry parameters or
electrocardiogram (ECG), as assessed by the Site Investigator, at the Screening visit
that would render the subject unsuitable for inclusion

- Treatment with another investigational drug (e.g., oral albuterol or salbutamol,
riluzole, carnitine, creatine, sodium phenylbutyrate, et.c), biological agent, or
device within 1-month of Screening or 5 half-lives of study agent, whichever is
longer. Treatment with valproate or hydroxyurea within 3-months of Screening. Any
history of gene therapy, antisense oligonucleotide therapy, or cell transplantation.

- Ongoing medical condition that according to the Site Investigator would interfere with
the conduct and assessments of the study. Examples are medical disability (e.g.,
wasting or cachexia, severe anemia, etc.) that would interfere with the assessment of
safety or would compromise the ability of the subject to undergo study procedures.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.



Age minimum: 2 Years
Age maximum: 12 Years
Gender: All

Health Condition(s) or Problem(s) studied

Spinal Muscular Atrophy

Intervention(s)

Procedure: Sham procedure

Drug: Nusinersen

Primary Outcome(s)

Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15 [Time Frame: Baseline and Month 15]

Secondary Outcome(s)

Number of Participants With Clinically Significant Weight Abnormalities [Time Frame: Baseline through Month 15]

Proportion of Participants That Achieved Walking With Assistance [Time Frame: Month 15]

Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15 [Time Frame: Baseline and Month 15]

Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results [Time Frame: Baseline through Month 15]

Number of New Motor Milestones Achieved Per Participant [Time Frame: Month 15]

Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure [Time Frame: Baseline through Month 15]

Number of Participants With Clinically Significant Laboratory Parameter Abnormalities [Time Frame: Baseline through Month 15]

Change From Baseline in Revised Upper Limb Module (RULM) Test [Time Frame: Baseline and Month 15]

Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs) [Time Frame: Baseline through Month 15]

Number of Participants With Clinically Significant Neurological Examination Abnormalities [Time Frame: Baseline through Month 15]

Number of Participants With Clinically Significant Physical Examination Abnormalities [Time Frame: Baseline through Month 15]

Number of Participants With Clinically Significant Vital Sign Abnormalities [Time Frame: Baseline through Month 15]

Proportion of Participants That Achieved Any New Motor Milestone at Month 15 [Time Frame: Month 15]

Proportion of Participants That Achieved Standing Alone [Time Frame: Month 15]

Secondary ID(s)

ISIS 396443-CS4

2014-001947-18

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Results

• Results available: Yes
• Date Posted: 22/02/2018
• URL: https://clinicaltrials.gov/ct2/show/results/NCT02292537